Single center experience of a vancomycin resistant enterococcal endocarditis cohort

Journal of Infection

Volumn 63, Issue 6, 2011, Pages 420-428

  Forrest, Graeme N ^a   Arnold, Ryan S ^b   Gammie, James S ^b   Gilliam, Bruce L ^b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Endocarditis; Hemodialysis; Organ transplantation; Vancomycin resistant enterococci

Indexed keywords

AMPICILLIN; DAPTOMYCIN; GENTAMICIN; LINEZOLID; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM; TIGECYCLINE;

ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIUM IDENTIFICATION; CENTRAL VENOUS CATHETERIZATION; CLINICAL ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG SENSITIVITY; EMBOLISM; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FEMALE; HEART VALVE PROSTHESIS; HEART VALVE SURGERY; HEMODIALYSIS; HOSPITAL INFECTION; HUMAN; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MITRAL VALVE DISEASE; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TERTIARY HEALTH CARE; TREATMENT DURATION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; CROSS INFECTION; ENDOCARDITIS, BACTERIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; VANCOMYCIN RESISTANCE;

EID: 82255162762     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.08.014     Document Type: Article

References (26)

1. Hidron A.I., Edwards J.R., Patel J., Horan T.C., Sievert D.M., Pollock D.A., et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008, 29:996-1011.
2. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39:309-317.
3. Salgado C.D., Farr B.M. Outcomes associated with vancomycin-resistant enterococci: a meta-analysis. Infect Control Hosp Epidemiol 2003, 24:690-698.
4. de Perio M.A., Yarnold P.R., Warren J., Noskin G.A. Risk factors and outcomes associated with non-Enterococcus faecalis, non-Enterococcus faecium enterococcal bacteremia. Infect Control Hosp Epidemiol 2006, 27:28-33.
5. Furtado G.H., Mendes R.E., Pignatari A.C., Wey S.B., Medeiros E.A. Risk factors for vancomycin-resistant Enterococcus faecalis bacteremia in hospitalized patients: an analysis of two case-control studies. Am J Infect Control 2006, 34:447-451.
6. Zaas A.K., Song X., Tucker P., Perl T.M. Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. Clin Infect Dis 2002, 35:1139-1146.
7. McDonald J.R., Olaison L., Anderson D.J., Hoen B., Miro J.M., Eykyn S., et al. Enterococcal endocarditis: 107 cases from the international collaboration on endocarditis merged database. Am J Med 2005, 118:759-766.
8. Stevens M.P., Edmond M.B. Endocarditis due to vancomycin-resistant enterococci: case report and review of the literature. Clin Infect Dis 2005, 41:1134-1142.
9. Li J.S., Sexton D.J., Mick N., Nettles R., Fowler V.G., Ryan T., et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000, 30:633-638.
10. Baddour L.M., Wilson W.R., Bayer A.S., Fowler V.G., Bolger A.F., Levison M.E., et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on rheumatic fever, endocarditis, and kawasaki disease, Council on cardiovascular disease in the young, and the Councils on clinical cardiology, stroke, and cardiovascular surgery and anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005, 111:e394-e434.
11. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing 19th, 2008, Approved Standard Document M100-S16, Clinical and Laboratory Standards Institute, Villanova, PA.
12. Forrest G.N., Roghmann M.C., Toombs L.S., Johnson J.K., Weekes E., Lincalis D.P., et al. PNA FISH for hospital acquired enterococcal bacteremia: delivering earlier effective antimicrobial therapy. Antimicrob Agents Chemother 2008, 52:3558-3563.
13. Fowler V.G., Miro J.M., Hoen B., Cabell C.H., Abrutyn E., Rubinstein E., et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005, 293:3012-3021.
14. Weber S.G., Miller R.R., Perencevich E.N., Tolentino J., Meltzer D., Pitrak D., et al. Prevalence of antimicrobial-resistant bacteria isolated from older versus younger hospitalized adults: results of a two-centre study. J Antimicrob Chemother 2009, 64:1291-1298.
15. Klevens R.M., Morrison M.A., Nadle J., Petit S., Gershman K., Ray S., et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007, 298:1763-1771.
16. Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., Rice L.B., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:1-12.
17. Fernandez-Guerrero M.L., Verdejo C., Azofra J., de Gorgolas M. Hospital-acquired infectious endocarditis not associated with cardiac surgery: an emerging problem. Clin Infect Dis 1995, 20:16-23.
18. Nori U.S., Manoharan A., Thornby J.I., Yee J., Parasuraman R., Ramanathan V. Mortality risk factors in chronic haemodialysis patients with infective endocarditis. Nephrol Dial Transplant 2006, 21:2184-2190.
19. Paterson D.L., Dominguez E.A., Chang F.Y., Snydman D.R., Singh N. Infective endocarditis in solid organ transplant recipients. Clin Infect Dis 1998, 26:689-694.
20. Cunha B.A., Mickail N., Eisenstein L.E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin. Heart Lung 2007, 36:456-461.
21. Mutnick A.H., Enne V., Jones R.N. Linezolid resistance since 2001: SENTRY antimicrobial surveillance program. Ann Pharmacother 2003, 37:769-774.
22. Johnson A.P., Woodford N. Glycopeptide-resistant Staphylococcus aureus. J Antimicrob Chemother 2002, 50:621-623.
23. Linden P.K. Optimizing therapy for vancomycin-resistant enterococci (VRE). Semin Respir Crit Care Med 2007, 28:632-645.
24. Figueroa D.A., Mangini E., modio-Groton M., Vardianos B., Melchert A., Fana C., et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009, 49:177-180.
25. Florescu I., Beuran M., Dimov R., Razbadauskas A., Bochan M., Fichev G., et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008, 62(Suppl. 1):i17-i28.
26. Schutt A.C., Bohm N.M. Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin. Ann Pharmacother 2009, 43:2108-2112.